User profiles for Margaret L Axelrod
 | Margaret L. AxelrodWashington University in St. Louis Verified email at wustl.edu Cited by 1105 |
T cells specific for α-myosin drive immunotherapy-related myocarditis
ML Axelrod, WC Meijers, EM Screever, J Qin… - Nature, 2022 - nature.com
Immune-related adverse events, particularly severe toxicities such as myocarditis, are major
challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy 1 . The …
challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy 1 . The …
Biological consequences of MHC-II expression by tumor cells in cancer
Immunotherapy has emerged as a key pillar of cancer treatment. To build upon the recent
successes of immunotherapy, intense research efforts are aimed at a molecular understanding …
successes of immunotherapy, intense research efforts are aimed at a molecular understanding …
A genetic mouse model recapitulates immune checkpoint inhibitor–associated myocarditis and supports a mechanism-based therapeutic intervention
We provide a preclinical model of ICI-associated myocarditis which recapitulates this clinical
syndrome. Using this model, we demonstrate that CTLA4 and PD-1 (ICI targets) functionally …
syndrome. Using this model, we demonstrate that CTLA4 and PD-1 (ICI targets) functionally …
Hydroxychloroquine as pre-exposure prophylaxis for coronavirus disease 2019 (COVID-19) in healthcare workers: a randomized trial
…, CP Skipper, KA Pastick, ML Axelrod… - Clinical Infectious …, 2021 - academic.oup.com
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly
emerging virus causing the ongoing coronavirus disease 2019 (COVID-19) pandemic with no …
emerging virus causing the ongoing coronavirus disease 2019 (COVID-19) pandemic with no …
Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer
ML Axelrod, MJ Nixon, PI Gonzalez-Ericsson… - Clinical Cancer …, 2020 - AACR
Purpose: The recent approval of anti-programmed death-ligand 1 immunotherapy in combination
with nab-paclitaxel for metastatic triple-negative breast cancer (TNBC) highlights the …
with nab-paclitaxel for metastatic triple-negative breast cancer (TNBC) highlights the …
Safety of hydroxychloroquine among outpatient clinical trial participants for COVID-19
…, DA Williams, AA Nascene, ML Axelrod… - Open forum …, 2020 - academic.oup.com
Background Use of hydroxychloroquine in hospitalized patients with coronavirus disease
2019 (COVID-19), especially in combination with azithromycin, has raised safety concerns. …
2019 (COVID-19), especially in combination with azithromycin, has raised safety concerns. …
Emerging biomarkers for cancer immunotherapy in melanoma
The treatment and prognosis of metastatic melanoma has changed substantially since the
advent of novel immune checkpoint inhibitors (ICI), agents that enhance the anti-tumor …
advent of novel immune checkpoint inhibitors (ICI), agents that enhance the anti-tumor …
Tumor-specific major histocompatibility-II expression predicts benefit to anti–PD-1/L1 therapy in patients with HER2-negative primary breast cancer
…, JD Wulfkhule, RI Gallagher, X Sun, ML Axelrod… - Clinical Cancer …, 2021 - AACR
Purpose: Immunotherapies targeting PD-1/L1 enhance pathologic complete response (pCR)
rates when added to standard neoadjuvant chemotherapy (NAC) regimens in early-stage …
rates when added to standard neoadjuvant chemotherapy (NAC) regimens in early-stage …
[HTML][HTML] Progesterone promotes immunomodulation and tumor development in the murine mammary gland
Background Clinical studies have linked usage of progestins (synthetic progesterone [P4])
to breast cancer risk. However, little is understood regarding the role of native P4, signaling …
to breast cancer risk. However, little is understood regarding the role of native P4, signaling …
[HTML][HTML] MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression
Aim: Immunotherapy and immune checkpoint inhibitors (ICI) have changed cancer care for
many patients; however, breast cancers have exhibited minimal response to single agent ICI …
many patients; however, breast cancers have exhibited minimal response to single agent ICI …
